Skip to main content
Equibles

Ikarian Capital, LLC

Position in ANRO — Alto Neuroscience, Inc.

CIK 1778253 DALLAS, TX
Back to ANRO Full portfolio

Position in ANRO

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$10,749,649
-$827,551 QoQ
Shares Held
407,338
-20.9% QoQ
Ownership
1.04%
of shares outstanding
% of Portfolio
1.74%
of 13F equity value
Holder Rank
#23
of 114 holders
Holding Since
Sep 2024
8 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in ANRO Over Time

Shares Held

Position Value (USD)

Derivatives in ANRO

reported options exposure · as of Sep 30, 2024
CallValue
$4,930,640
CallShares
431,000
PutValue
$5,148,000
PutShares
450,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Ikarian Capital, LLC holds $559,861,982 across 103 Biotechnology names. ANRO ranks #18 (1.9% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ABVX
Abivax S.A.
 328,635 $43,793,900
2 KOD
Kodiak Sciences Inc.
 1,059,730 $41,287,080
3 ALMS
Alumis Inc.
 870,548 $24,497,220
4 PRAX
Praxis Precision Medicines, Inc.
 72,842 $24,386,773
5 PCVX
Vaxcyte, Inc.
 388,682 $22,594,084
6 CLDX
Celldex Therapeutics, Inc.
 478,500 $17,804,985
7 RCUS
Arcus Biosciences, Inc.
 504,559 $15,555,553
8 RLMD
Relmada Therapeutics, Inc.
 2,148,359 $14,866,644

All Filings in ANRO

Export CSV
9 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $10,749,649 407,338
2026-03-31 $11,577,200 515,000
2025-12-31 $9,167,000 515,000
2025-09-30 $442,200 110,000
2025-06-30 $242,000 110,000
2025-03-31 $378,000 175,000
2024-12-31 $1,480,500 350,000
2024-09-30 $4,930,640 431,000
2024-09-30 $5,148,000 450,000